Purpose: Unverricht-Lundborg disease (EPM1) is the most common form of progressive myoclonus epilepsies. The genetic background is a homozygous dodecamer repeat extension mutation in the cystatin B (CSTB) gene. However, mutations occurring in a compound heterozygous form with the expansion mutation have also been reported. In Finland, we have found five EPM1 patients compound heterozygous for the dodecamer repeat expansion and the c.202C>T mutation in the CSTB gene (chEPM1). There are no previous clinical or neurophysiological studies on these patients. Thus, we aimed to characterize possible functional alterations in primary motor cortical areas. Methods: Five chEPM1 patients were compared with homozygous patients and healthy controls. All patients underwent a clinical evaluation to characterize the severity of the symptoms. Navigated transcranial magnetic stimulation (TMS) was used to study cortical excitability by determining the motor thresholds (MT), silent periods (SP) and motor evoked potential (MEP) characteristics. Continuous electroencephalography (EEG) was recorded during the measurements. Voxel-based MRI morphometry (VBM) was used to study differences in gray matter volume. Results: The chEPM1 patients exhibited an inhibitory cortical tonus reflected as elevated MTs and prolonged SPs. EEG showed spontaneous focal epileptiform activity in centro-temporal and parietal areas in addition to more widespread and generalized discharges. VBM revealed loss of gray matter volume in primary motor cortical areas and thalami. Discussion: The chEPM1 patients exhibited functional and structural changes in primary motor cortical areas. The functional changes are more profound as compared to homozygous patients, suggesting a neurophysiological background for the more severe clinical symptoms.
ß 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
form of the disease. 5 In this paper, patients with these specific mutations are referred to as compound heterozygotes (chEPM1). In early studies on EPM1 the diagnosis of the condition was based almost exclusively on clinical characteristics, and thus, the genetic background of the patients may have been non-uniform. Therefore it is essential to re-evaluate the clinical and neurophysiological characteristics in genetically verified EPM1 patients. In addition, the existence of possible genotype-phenotype correlations should be explored.
There are no previous clinical or neurophysiological studies on chEPM1 patients. However, generally myoclonus is regarded to derive from abnormally increased cortical excitability with a contribution of impaired cortical inhibition, [11] [12] [13] which is consistent with findings in various forms of PMEs, including EPM1. [14] [15] [16] [17] Typical EEG findings in EPM1 include normal or moderately slow background activity and generalized fast spike or polyspike-wave discharges that can occur either spontaneously or provoked by exogenous stimuli. 6, 18, 19 Transcranial magnetic stimulation (TMS) is a non-invasive method applicable for the evaluation of cortical excitability. 20 The stimulation can be targeted precisely and repeatedly using MRInavigated TMS. 21, 22 Typical TMS parameters for studying cortical excitability include the cortical motor threshold (MT) and the silent period (SP). The MT decreases in hyper-excitable states and, respectively, increases due to inhibition. 23 The SP is prolonged due to inhibition and shortened in hyper-excitable states. 24 We studied possible functional and structural changes of the primary motor cortex in all the known chEPM1 patients in Finland. The results were compared with findings from homozygous EPM1 patients from our previous study, in which elevated MTs and the absence of age-related shortening of SP duration were reported as the main TMS characteristics. 25 All the results were also compared to age-matched healthy controls. MRI-navigated TMS was used to study the excitability of the motor cortex, and voxel-based morphometry to assess structural changes in the very same cortical areas. Simultaneous conventional EEG was used to monitor possible changes in spontaneous epileptiform activity. The main aim was to explore possible differences between these two genotypes, especially related to their primary motor systems.
Patients and methods

Subjects
This study is a part of a large ongoing 4-year-study, carried out at Kuopio Epilepsy Center, Kuopio University Hospital, jointly with Neuroscience Center and Folkhä lsan Institute of Genetics, Helsinki University. All the patients were evaluated in the ongoing clinical and molecular genetics study. The patients had either participated in our previous studies or were referred to the center during the study. Five genetically verified EPM1 patients, compound heterozygous for the dodecamer repeat expansion and the c.202C>T mutation in the CSTB gene, were enrolled in the study. Demographic and clinical data on the patients are provided in Table 1 . The data from chEPM1 patients were compared with healthy control subjects (n = 65) and homozygous patients (n = 24), which were obtained from pre-existing databases previously published by the authors. 25, 26 The study was conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). The Ethical Committee of Kuopio University Hospital approved the study protocol and informed consent was obtained from all participants.
Clinical assessment of the EPM1 patients
Medical history of the patients was collected retrospectively using the health institutions' medical records and by interviewing the patients and their relatives. A Unified Myoclonus Rating Scale (UMRS) test panel was performed as a part of clinical patient evaluation. The testing was video-recorded and evaluated using a standard protocol. 27 In this study the myoclonus with action score (AM, max. score 160) and functional test (FT, max. score 28) (UMRS Sections 4 and 5, respectively) were used to assess the severity of myoclonus of the patients. Higher UMRS scores indicate more severe myoclonus.
Navigated TMS measurement setup and protocol
TMS was performed using an eXimia stimulator and a biphasic figure-of-eight coil (Nexstim Ltd., Helsinki, Finland). Navigated TMS was utilized to target the stimulations at desired locations and to keep the coil positioning stable throughout the measurement (eXimia NBS system, version 2.2.0; Nexstim Ltd., Helsinki, Finland). Individual 3D T1-weighted MR images (1.5T Siemens Magnetom Avanto; Erlangen, Germany) were used for navigation. MEPs were recorded from the thenar muscle (abductor pollicis brevis, APB) by continuous and stimulus-locked EMG (ME 6000, Mega Electronics Ltd., Kuopio, Finland). EEG recording was performed using a TMScompatible eXimia EEG system (Nexstim Ltd., Helsinki, Finland).
All procedures were performed identically on both hemispheres. The MT of the APB was determined at the optimal cortical representation area using a similar protocol as previously described. 26, 28 Thereafter 10 pulses were applied to the optimal location at an intensity of 120% of the MT to determine the mean amplitude and latency of the MEP responses. The electric fields induced by stimulating at the MT intensity were computed using the NBS software. This allowed the evaluation of cortical excitability also by comparing the induced maximum electric field strengths (EFs).
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Maximum voluntary muscle contraction (MVC) for each subject was determined using bimanual force grips (NewTest, Oulu, Finland). 40% of the MVC was used for SP measurements. SPs were determined by averaging 5 consecutive trials, induced with 120% of the MT intensity. 28, 29 Due to clinically common impairment in muscle control in EPM1 patients, MVC could not be determined for all subjects. In such cases patients were given flexible objects to squeeze in their hands in order to induce contraction of the thenar muscles, since the duration of the SP has been found to be unaffected by muscle force.
28,30-34
EEG recording
Continuous scalp EEG was recorded with a 64-channel TMScompatible amplifier. 35 An electrode cap was tightly attached to the subject's head. All electrodes were referred to an electrode placed on the right mastoid. The data was recorded with a 1450-Hz sampling frequency and 16-bit precision. A trigger signal marking each TMS pulse was recorded with the EEG. Vertical electro-oculogram (EOG) was recorded above and below the left eye. Throughout the measurement session on-line EEG was monitored by an experienced clinical neurophysiologist to detect possible alterations in cortical excitability. The recorded EEG was stored for further off-line analysis.
MRI voxel-based morphometry (VBM)
The MR images were processed using optimized voxel-based morphometry (VBM), 36 with the VBM2-toolbox (http://dbm.neuro.uni-jena/vbm/) in SPM2 (Wellcome Department of Imaging Neuroscience, London, UK; www.fil.ion.ac.uk/spm) running under Matlab 6.5 (Mathworks, Inc.). Based on the areas of gray matter volume, a VBM analysis was performed comparing the chEPM1 patients with homozygous patients and healthy controls. 37 The level of significance was p < 0.05, corrected with the false discovery rate method for multiple comparisons.
Data analysis
The MTs were analysed as percentage of maximum stimulator output as well as induced EFs. The EMG recordings from individual subjects were analysed using MegaWin software (Mega Electronics Ltd., Kuopio, Finland). To enable a comparison with the normative values of healthy control subjects, a correction method was used to estimate and reduce the effect of the electrode cap on the MT, as it increases the coil-cortex distance, and thus elevates the MT. 38 The
EFs were determined at a uniform depth of 25 mm from the scalp and thus take into account the variation in the coil-to-scalp distance. Therefore, the EFs are comparable between the patients and the control subjects regardless of whether an electrode cap was used or not. The measured MEP latencies were corrected with subject's height and age. 26 Due to the limited number of chEPM1 patients the TMS results were not analysed on group-level. Thus, the TMS results of the chEPM1 patients were compared to the healthy controls, as well as to homozygous EPM1 patients by calculating a two-tailed Zscore for each parameter separately for all studied subjects. Z-scores of less than À1.96 or more than 1.96 were regarded as significant (p < 0.05). Normal distribution of both control populations was verified using the Kolmogorov-Smirnov test.
Results
The age of onset of the disease was lower in chEPM1 patients as compared to the homozygous EPM1 group (7 AE 2 years vs. 10 AE 2 years, respectively). The chEPM1 patients also tended to have higher scores in the UMRS AM and FT scales (Table 1 ). However, due to the small number of patients, a group-comparison analysis could not be performed reliably.
The TMS results revealed altered cortical excitability in chEPM1 patients ( Table 2 ). In two patients, measurable MEPs could not be elicited even at maximal stimulator output intensity, and thus, their MTs could not be determined. Since the MT is required for the determination of further TMS parameters, these parameters could not be determined either for these two patients with indeterminable MTs. On the left hemisphere of patient 5 the MEP and SP characterization could not be performed at 120% of the MT intensity due to the high initial MT value (85%). Thus, further stimulations were performed at 99% of stimulator output intensity corresponding approximately 116% of the MT.
The EEG was abnormal in all of the studied chEPM1 patients (Table 3) . They exhibited mild-to-moderate slowing of background activity in addition to both focal and generalized epileptiform activity (Fig. 1) . Focal epileptiform activity could be observed in all patients on both hemispheres in frontal and central head regions, and at times also in more lateral temporal regions in four patients. Interictal focal spikes and sharp waves appeared separately or in series lasting up to 3 s, or as a focal electrographic seizures lasting up to 10 s. There was, however, no clinical correlation for the focal EEG abnormalities or any electrical build-up that would suggest an ictal nature. In addition to focal abnormalities, generalized polyspike-wave discharges were also observed in four patients. TMS did not produce any aggravation of clinical myoclonus, nor were there any EEG features of enhanced excitation. The VBM analysis revealed gray matter volume loss in bilateral cortical motor areas and thalami (Fig. 2 ) in chEPM1 patients as compared to healthy controls. However, there were no evident group-level differences in comparison with homozygous patients.
Discussion
Unverricht-Lundborg disease (EPM1) patients compound heterozygous for the dodecamer repeat expansion and the c.202C>T mutation in the CSTB gene exhibited marked functional changes in cortical excitability and reduced gray matter volume in primary cortical motor areas. Their EEGs revealed also evidence of focal epileptiform activity in the same cortical regions. We believe that these observations are relevant to the underlying [ ( ) T D $ F I G ] pathophysiology of their most devastating clinical symptom, i.e., myoclonus.
The generation of myoclonus is associated with an imbalance of excitatory and inhibitory neuronal circuits, which may be generated in any part of the central nervous system. 12, 15, 39, 40 In EPM1, it is regarded as epileptic, i.e., of cortical origin. 41 However, in addition to pure cortical myoclonus, the myoclonus in EPM1 may also be generated by a mechanism requiring a somatosensory trigger, with both, a cortical and a subcortical contribution. 11, 42 There are no previous TMS studies on cortical excitability in chEPM1 patients, but in studies on various forms of PMEs the generation of myoclonus is regarded to derive from hyperexcitable responses to sensory stimuli, which trigger the motor responses due to a lack of cortical inhibition. Furthermore, aberrant neuronal loops have been proposed as a possible mechanism. [14] [15] [16] [17] However, in addition to cortical hyperexcitability, few studies also reported evidence of increased inhibition, reflected as elevated MTs. This was supported by findings from a large-scale study on genetically verified homozygous EPM1 patients. 16, 17, 25 The major drawbacks of most previous studies are the heterogeneity and limited number of subjects, as different forms of PMEs have been reported to exhibit some peculiar characteristics of cortical excitability. 14, 43 Thus, the discrepancies between the results from studies lacking a genetic verification of the disease form should be interpreted with caution and suggest a need for re-evaluation. The current findings in chEPM1 patients cohere with the previous findings in genetically verified EPM1, since all of our patients exhibited abnormal characteristics of cortical excitability reflected as elevated MTs in comparison with healthy controls (Table 2) . Our results suggest also that these alterations may be more profound in chEPM1 patients as compared to homozygous patients. However, due to the indeterminably high MTs in two patients along with the small number of subjects this assumption lacks statistical evidence. Elevated MT is associated with either reduced cortical excitability or increased inhibition, and thus, is a rather paradoxical finding in patients with epileptic myoclonus. In previous studies elevated MT has therefore been attributed to the use of anti-epileptic drugs (AEDs). 15, 16 The difference of the MT in comparison to healthy controls may result from AEDs at least to a certain extent, since many of them have been reported to increase the MT. [44] [45] [46] [47] [48] [49] [50] [51] In EPM1 similar medication is used with individually adjusted maximum tolerated dosages regardless of the precise genetic background, and thus, differences between these groups unlikely derive completely from differences in AED use. Additionally, no correlation between dosage and MT has been established for most AEDs, especially when used in different combinations as in EPM1. Furthermore, normal MTs have also been reported in patients treated with AEDs. 17 Therefore we hypothesize that the higher MTs in chEPM1 may be partially explained by a more severe disease form, reflecting a possible reactive mechanism to increased excitability. The studied chEPM1 patients exhibited prolongation in MEP latencies in comparison with healthy controls (Table 2 ). In one subject the difference was significant also in comparison with homozygous patients. Prolongation of MEP latencies has been reported also in homozygous patients in some previous studies. 14, 15, 17 MEP latencies may, however, be affected by various pathological processes of the central and peripheral nervous system in addition to co-existing other clinical conditions. In our study population, the large age variation and the use of AEDs may act as confounding factors in the MEP analysis. Thus, further studies are required to determine, whether this finding can be attributed to the actual disease process. The SPs were prolonged in chEPM1 patients as compared to healthy subjects, and showed a tendency towards prolongation even in comparison with homozygous EPM1 patients ( Table 2) . Previously prolonged SP durations have been reported as a peculiar finding in homozygous EPM1 patients. 25 In epilepsies caused by a focal cortical lesion, the SPs have been reported to be shortened in the epileptogenic hemisphere and to be prolonged on the contralateral side. Thus, the prolongation of the SP is regarded as a reactive phenomenon to balance out the hyper-excitability induced by the epileptogenetic focus. 42 In chEPM1 patients, the prolonged SPs may therefore be interpreted to reflect a reactive inhibitory mechanism to the underlying hyperexcitable process. The effect of AEDs on SP-duration remains debatable, since previous data is highly inconsistent. Normal, shortened and prolonged SPs have been attributed to the AEDs used by our study subjects, [44] [45] [46] [47] 50, 51, 53 and thus, the observed uniform prolongation of the SPs is unlikely explained by mere AED effects. VBM revealed significant gray matter volume loss bilaterally in the primary motor areas and thalami supporting the role of the primary motor areas in the pathophysiology of chEPM1 (Fig. 2) . The volume loss in the thalami coheres with previously reported thalamostriatal dopaminergic defects in EPM1 52 suggesting a possible contributing pathophysiological thalamocortical mechanism. There were no significant differences in the VMB results between chEPM1 patients and homozygous patients, possibly due to the limited number of chEPM1 subjects not allowing the detection of subtle group-level differences. However, it may also be that the difference between the genotypes is only functional, and thus, remains undetectable by anatomical imaging methods. All studied chEPM1 subjects exhibited spontaneously abnormal EEG characteristics (Table 3 ). The background activity was slowed in all subjects, and furthermore, both focal and generalized epileptiform activity was observed (Fig. 1) . In homozygous EPM1 patients, normal or moderate slowing of background activity and generalized fast spike or polyspike-wave (PSW) discharges have been reported as common EEG findings. There is also evidence of electrophysiological and clinical stimulus-sensitivity. 6, 18, 19, 54 Even though focal EEG abnormalities have been described in some forms of PME, 55 it is not a typical finding in EPM1. However, in all the studied chEPM1 patients, focal EEG activity could be observed on both hemispheres in frontal and central regions, and at times also in more lateral temporal regions in four patients. Thus, the EEG in chEPM1 more commonly contains focal epileptiform activity in comparison to previously reported findings in homozygous EPM1. The epileptiform EEG features in homozygous EPM1 have been also reported to gradually decline over time along with clinical reduction of seizure frequency. 56, 57 Due to the relatively young age of our patients, it cannot be stated, whether the EEG abnormalities in chEPM1 are more persistent over time correlating with a more severe clinical picture. We, however, did not observe a similar conclusive decline of epileptiform activity even in patients with a disease duration of over 20 years. The studied chEPM1 patients present unique characteristics in both TMS parameters and EEG recordings that are more pronounced than in EPM1. The findings imply a disturbed balance between excitatory and inhibitory neuronal functions within primary motor cortical areas, which is supported by the VBM data, as the structural gray matter volume loss is also detectable at primary motor areas. The disturbed function of the primary motor cortex is manifested also in the clinical evaluation, where chEPM1 patients presented more profound action myoclonus reflected as higher UMRS scores. Since the basic pathophysiology of myoclonus is attributed to enhanced neuronal excitability we conclude that the inhibitory tonus observed in chEPM1 is a reactive mechanism to the disease process, especially to the devastating myoclonus. The distinct pathophysiology of the compound heterozygous form of EPM1 with the dodecamer repeat expansion and the c.202C>T mutation in the CSTB gene may result in a more severe form of the disease, and thus, also the reactive inhibitory phenomena are more evident.
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